Financial Performance & Growth - Clover Health anticipates insurance revenue of $1.8 billion to $1.875 billion for full year 2025[50] - The company projects Adjusted EBITDA between $50 million and $70 million for full year 2025[9, 50] - Clover Health expects a 32% year-over-year increase in Medicare Advantage (MA) membership in 2025[9, 44] - Clover Health's Insurance Benefits Expense Ratio (BER) for the first half of 2025 was 87.3%[24] Clover Assistant & Clinical Outcomes - Clover Assistant (CA) is associated with earlier diagnosis of Chronic Kidney Disease (CKD) by approximately 18 months on average[18] - Clover Assistant is associated with 15% lower all-cause hospitalizations and 18% lower 30-day readmissions for members with Chronic Obstructive Pulmonary Disease (COPD)[18, 20] - Clover Health achieved a 4.94 out of 5 Stars on HEDIS measures for Star Rating year 2025, the top-performing score on core HEDIS measures for Medicare Advantage plans with over 2,000 members nationwide[18] Strategic Initiatives - Clover Health is focused on a ~$500 billion market with over 35 million seniors enrolled in Medicare Advantage[8] - Clover Health's Counterpart Health subsidiary aims to expand the company's care model to more plans and providers[8] - Approximately 97% of Clover Health's membership is enrolled in PPO plans[8, 49]

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Centene Corporation ("Centene" or the "Company") (NYSE: CNC) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Centene investors who were adversely affected by alleged securities fraud between December 12, 2024 and June 30, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/centene-corporation-lawsuit-submi ...

Group 1 - UnitedHealth Group is experiencing its worst performance since 2008, with the stock down approximately 50% this year, closely approaching the 2008 decline of -54.3% [1] Group 2 - The investment strategy focuses on GARP (growth at a reasonable price) stocks while also seeking opportunities in other areas, with no specified time horizon for investments [2] - The analyst has developed market-beating algorithms using Python to identify attractive investment opportunities within their portfolio [2] - The analyst has experience working at TipRanks as an analysis/news writer and editor, which has enhanced their understanding of market interests and the importance of accurate information [2]

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Centene Corporation ("Centene" or the "Company") (NYSE: CNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Centene investors who were adversely affected by alleged securities fraud between December 12, 2024 and June 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/centene-corporation-lawsuit ...

Core Insights - Elevance Health, Inc. (ELV) has experienced a significant decline of 20.3% year to date, underperforming compared to industry peers and the S&P 500 Index [1][7] - The stock closed at $293.99, near the lower end of its 52-week range of $273.71–$567.26, potentially presenting an attractive entry point for value investors [1] - Elevance has a market capitalization of $66.2 billion, with peers like UnitedHealth Group and Centene also facing challenges this year [1] Membership and Revenue Challenges - Medicaid membership has decreased by 15.1% in 2024 and an additional 4.1% in the first half of 2025, impacting revenue [4] - Membership in Medicare Supplement and employer group risk-based segments is also declining, with expectations of continued volatility into 2026 due to recent policy changes [4][6] Rising Costs and Margin Pressure - Medical costs are increasing due to higher utilization, leading to a deterioration in the benefit expense ratio, which worsened by 260 basis points year over year to 88.9% in Q2 [5] - The full-year benefit expense ratio is projected to be around 90%, with expectations of further increases in the second half of the year [5] Analyst Sentiment and Earnings Outlook - Management has revised its full-year 2025 adjusted EPS outlook down to approximately $30, from a previous range of $34.15-$34.85, reflecting a decline from the 2024 figure of $33.04 [6] - Analysts have sharply cut 2025 and 2026 EPS estimates, with the current consensus estimate for 2025 EPS at $30.59, indicating a 7.4% decline from the prior year [9] Valuation Metrics - Elevance Health trades at a forward 12-month P/E of 9.24X, significantly below its five-year median of 13.44X and the industry average of 14.32X, indicating investor caution [10] - Despite a steeper sell-off, peers UnitedHealth and Centene command higher multiples of 14.05X and 9.94X, respectively [10] Long-Term Growth Potential - Elevance has solid long-term growth drivers, including product expansion, revenue diversification, and premium increases, which may help mitigate current pressures [11] - The company is reallocating resources to more profitable areas and has a return on invested capital of 9.36%, outperforming the industry average of 5.80% [12] Shareholder Value Initiatives - Elevance maintains consistent dividend payouts with a yield of 2.33%, higher than the industry average of 1.37% [13] - The company repurchased shares worth $379 million in Q2 2025, with approximately $8 billion remaining under its buyback authorization as of June 30, 2025 [13]

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Centene Corporation (NYSE: CNC) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Centene, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/centene-corporation-class-action-lawsuit. Investors have until September 8, 2025, to ask the ...

Group 1 - The company maintains a bullish rating on UnitedHealth Group (NYSE: UNH) due to the addition of 770,000 new members served in Q2 2025 [1] - The analyst emphasizes a high likelihood of continued growth for UNH based on its current performance metrics [1] - The approach taken by the analyst involves breaking down complex financial and technological problems to identify overlooked investment opportunities [1] Group 2 - The analyst has a strong background in investment, private equity, and venture capital, which supports the credibility of the insights provided [1] - The focus of the articles includes emerging technologies, sustainable investing, and the intersection of innovation and finance [1] - The analyst expresses a commitment to sharing insights and learning from fellow investors to drive positive change in the investment landscape [1]

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Centene Corporation (NYSE: CNC) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Centene, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/centene-corporation-class-action-lawsuit. Investors have until September 8, 2025, to ask the ...

NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Centene Corporation ("Centene" or the "Company") (NYSE: CNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Centene investors who were adversely affected by alleged securities fraud between December 12, 2024 and June 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/centene-corporation-lawsuit ...

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene's enrollment a ...